This Phase 1 study is intended to explore the safety, tolerability, pharmacodynamics and
efficacy of topical CyPep-1 as a potential treatment for HPV-associated conditions. Since
this is a first-on-human study of a topical formulation, the first subjects will be monitored
more frequently in order to establish the safety profile. Because clinical outcomes (i.e.
reduction/clearance of the lesion) often require lengthy treatment / observation periods, the
study design will primarily utilize clinical measurements of wart dimensions, along with HPV
viral load as a biomarker of anti-viral effect.